Netherlands -- Dutch biotechnology company Mucosis B.V. announced today that John Lambert was
elected as member and chair of its Supervisory Board. Having held various key positions
at pharmaceutical and biotech companies in both the United States and Europe, Mr.
Lambert brings exceptional vaccine industry experience to Mucosis.
From 1998 to 2000 Mr. Lambert was President at Aventis Pasteur MSD, a vaccine joint
venture established between Aventis (now sanofi-aventis Group) and Merck & Co, Inc.
Subsequently, from 2001 to 2005, he served as President of Chiron Vaccines (now
Novartis Vaccines). Mr. Lambert was a non-executive Director at Acambis Plc (U.K.),
chairman of the Conseil d’Administration of Farmaprojects S.A. (Spain), non-executive
chairman of Cambridge Biostability Ltd. (U.K.) and advisor for Crucell N.V.
(Netherlands) on acquisitions and strategy. He is currently Board Director of Novavax
“I look forward to joining the Supervisory Board of this exciting company,” commented
Mr. Lambert. “Mucosis is on track to successfully develop Mimopath™-based vaccines
as an innovative approach to meeting worldwide health needs. I believe that this
technology holds great potential.”
Govert Schouten, Chief Executive Officer of Mucosis, added: “We are very happy to
welcome an industry professional of such caliber and experience. Mr. Lambert’s expertise
will be important for our company’s ability to build value.”
For further information please contact:
+31 (6) 55320948
Mucosis B.V. is a Dutch biotechnology company that has developed a proprietary
vaccine platform technology, Mimopath™ , on which it develops mucosal vaccines with
improved efficacy. Mucosis’s lead products are FluGEM™, a vaccine to prevent
influenza, and PneuGEM™, a vaccine preventing diseases caused by pneumococcal
bacteria. Mimopath™ -based vaccines can be administered needle-free in the nose and
mouth, evoking a more natural immune response with a broader base of protection.
About Mimopath™ technology
Mucosis’s Mimopath™ technology is based on Lactococcus lactis, a safe bacterium
commonly used in the food industry. Mucosis has developed a robust technique to
formulate the L. lactis bacteria into non-living bacterium-like particles (BLPs) that can be
loaded with antigens from viral, bacterial, parasitic or tumor origin. The antigen-covered
BLPs form a vaccine that can be delivered into the nose or mouth, without the need for
a needle. These vaccines raise protective immunity by activation of both the innate and
the adaptive immune system.